Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shDSG3
- Development stage
- Preclinical
- Lead developer
- Chang Gung University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
shDSG3 is a short hairpin RNA (shRNA) designed to silence the expression of Desmoglein 3 (DSG3), a protein that acts as an oncogene in head and neck cancers (HNCs). By suppressing DSG3, the drug disrupts the interaction between DSG3 and plakoglobin, leading to the translocation of plakoglobin from the cytoplasm to the nucleus. This translocation inhibits TCF/LEF transcriptional activity, subsequently downregulating downstream oncogenic targets such as c-myc, cyclin D1, and MMP7. Research conducted at Chang Gung University has demonstrated that shDSG3 reduces cell growth, colony formation, migration, and invasion in HNC cell lines and inhibits tumor growth in xenograft mouse models.
- Other names
- short hairpin DSG3-RNAiDSG3-shRNADSG-3-shRNADSG 3-shRNA
02
Targets
TLR7/8 (Toll-like receptor 7 and Toll-like receptor 8)IFIH1 (MDA5)Desmoglein 3 (DSG3) mRNAEIF2AK2 (Interferon-induced protein kinase R)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on shDSG3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shDSG3.